Monroe Jackson Stutts

6420347, Jul 16, 2002

Jul 17, 1998

09/101840

Karla M. Jacobus - Cary NC
Benjamin R. Yerxa - Raleigh NC
William Pendergast - Durham NC
Janet L. Rideout - Raleigh NC
David J. Drutz - Chapel Hill NC
Michael K. James - Raleigh NC
Monroe Jackson Stutts - Chapel Hill NC
Cary Geary - Seattle WA
Edwardo R. Lazarowski - Chapel Hill NC

Inspire Pharmaceuticals, Inc. - Durham NC
The University of North Carolina at Chapel Hill - Chapel Hill NC

A61K 3170

514 51, 514 48, 514 47

A method of stimulating ciliary beat frequency in a subject in need of such treatment is disclosed. The method comprises administering to the airways, ears, eyes, or genito-urinary tract of the subject a triphosphate nucleotide such as uridine 5â-triphosphate (UTP), an analog of UTP, or any other analog, in an amount effective to stimulate ciliary beat frequency. This method is useful for treating patients afflicted with ciliary dyskinesia, Kartageners syndrome, or any other disease involving dysfunction of ciliary movement, such as male infertility caused by impairment of propulsion of the spermatozoa or immune deficiency caused by impairment of ciliary movement in neutrophils or macrophages. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include any liquid suspension (including nasal spray or nasal or eye drops), oral, inhaled by nebulization, topical, injected, suppository, intra-operative by instillation or application, or ex vivo direct application to spermatozoa.

6673779, Jan 6, 2004

Jun 5, 2002

10/163804

Karla M. Jacobus - Cary NC
Benjamin R. Yerxa - Raleigh NC
William Pendergast - Durham NC
Janet L. Rideout - Raleigh NC
David J. Drutz - Chapel Hill NC
Michael K. James - Raleigh NC
Monroe Jackson Stutts - Chapel Hill NC
Cara Geary - Cincinnati OH
Eduardo R. Lazarowski - Durham NC

Inspire Pharmaceuticals, Inc. - Durham NC
The University of North Carolina at Chapel Hill - Chapel Hill NC

A61K 3170

514 51, 536 2621

The present invention is directed to a method of stimulating ciliary beat frequency to promote mucociliary or cough clearance of retained mucus secretions from the lungs, sinuses, upper airways, ears, eyes, genito-urinary tract, spermatozoa, ovaries, fallopian tubes, neutrophils, and macrophages of a patient. The method comprises administering uridine triphosphates, adenosine triphosphates, cytidine triphosphates, or dinucleoside tetraphosphates and the derivatives thereof to an affected body of a patient, to treat dysfunction of the mucociliary clearance system as a result of impaired ciliary movement in the patient.

20010041682, Nov 15, 2001

May 7, 2001

09/850609

Monroe Stutts - Chapel Hill NC, US
Richard Boucher - Chapel Hill NC, US
Eduardo Lazarowski - Durham NC, US
Cara Geary - Seattle WA, US

A61K031/7076
A61K031/7068

514/047000, 514/051000

A pharmaceutical formulation comprises, in an amount effective to hydrate lung mucous secretions, a compound of Formula (I): wherein n is from 1 to 6; X is —OH or —SH; A and B are each independently selected from the group consisting of:  wherein R is H or Br; or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A method of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I as given above, is also disclosed.

20120115795, May 10, 2012

May 28, 2010

13/321617

Robert Tarran - Chapel Hill NC, US
Monroe Jack Stutts - Chapel Hill NC, US
Scott Donaldson - Chapel Hill NC, US

A61K 38/14
C07H 21/04
C12N 5/02
C07K 14/435

514 209, 530395, 536 235, 435375

The present invention relates to the ability of PLUNC proteins, such as SPLUNC1 and SPLUNC2, to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of PLUNC proteins to sodium channels.

62352660, May 22, 2001

Apr 30, 1999

9/303491

Monroe Jackson Stutts - Chapel Hill NC
Richard C. Boucher - Chapel Hill NC
Eduardo R. Lazarowski - Durham NC
Cara A. Geary - Seattle WA

The University of North Carolina at Chapel Hill - Chapel Hill NC

A61K 912

424 45

A pharmaceutical formulation comprises, in an amount effective to hydrate lung mucous secretions, a compound of Formula (I): ##STR1## wherein n is from 1 to 6; X is --OH or --SH; A and B are each independently selected from the group consisting of: ##STR2## wherein R is H or Br; or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A method of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I as given above, is also disclosed.

57169314, Feb 10, 1998

May 2, 1995

8/431659

Luis Miguel Molina y Vedia - Chapel Hill NC
Monroe Jackson Stutts - Chapel Hill NC
Richard C. Boucher - Chapel Hill NC
David C. Henke - Chapel Hill NC

Molichem Medicines, Inc. - Chapel Hill NC

A61L 904
A61K 914
A61K 3800

514 12

A method of facilitating the clearance of retained pulmonary secretions in a subject using lantibiotics is disclosed. The method comprises administering to the lungs of the subject an effective amount of a lantibiotic. The lantibiotic is preferably administered by topically applying it to the respiratory epithelia, such as by generating an aerosol thereof which is then inhaled by the subject. A preferred lantibiotic for carrying out the present invention is duramycin. The method may be used in treating disorders such as cystic fibrosis, chronic bronchitis, and asthma. Also disclosed is a method of combatting tuberculosis comprising administering a lantibiotic to a subject in need of such treatment.

56351607, Jun 3, 1997

Jun 7, 1995

8/486988

Monroe J. Stutts - Chapel Hill NC
Richard C. Boucher - Chapel Hill NC
Eduardo R. Lazarowski - Durham NC
Cara A. Geary - Chapel Hill NC

The University of North Carolina at Chapel Hill - Chapel Hill NC

A61K 912

424 45

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is disclosed: ##STR1## wherein: n is from 1 to 6; X is --OH or --SH; A and B are each independently selected from the group consisting of: ##STR2## wherein R is H or Br. The compounds are useful in the treatment of airway diseases such as cystic fibrosis. Pharmaceutical formulations comprising a compound of Formula (I), and methods of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I as given above, are also disclosed.

56562560, Aug 12, 1997

Dec 14, 1994

8/355650

Richard C. Boucher - Chapel Hill NC
Monroe Jackson Stutts - Chapel Hill NC

The University of North Carolina at Chapel Hill - Chapel Hill NC

A61K 912

424 45

Method of hydrating lung mucous secretions in the lungs of a subject are disclosed. The methods involve administering benzamil or phenamil to the lungs of the subject in an amount effective to hydrate lung mucous secretions. The administering step is preferably carried out by inhalation administration. The method is useful in the treatment of diseases such as cystic fibrosis and chronic bronchitis.